No abstract

No abstract

Two high molecular weight antigens with molecular masses approximately 100 kDa and 130 kDa were identified by immunoblotting camel hydatid cyst fluid, with 94% sensitivity in sera from surgically confirmed Libyan cystic echinococcosis cases. 40% of sera from surgically confirmed alveolar echinococcosis cases cross-reacted with the 100 and 130 kDa antigens, as did 5.3% of sera from human Taenia solium cysticercosis patients. No cross-reaction occurred with sera from human schistosomiasis mansoni or onchocerciasis patients. In addition, all sera from patients with non-hydatid space-occupying lesions (i.e. simple liver cysts, kidney cysts, lung tuberculosis, pulmonary carcinoma, pulmonary empyema, and lung abscess) were seronegative against the same antigens, as were control serum samples from healthy individuals. The 100 and 130 kDa antigens were strongly recognized by sera from cystic echinococcosis patients when camel or horse hydatid cyst fluid was used in immunoblotting but were only weakly recognized if sheep or human hydatid cyst fluid was used. Camel hydatid cyst fluid could be an important source of diagnostic antigens for human cystic echinococcosis in the Middle East endemic region.

No abstract

No abstract

Background: Post transfusion hepatitis B (PTHB) continues to be an important public health concern in regard to blood transfusion in Libya. The inclusion of tests specifically for the hepatitis B surface antigen (HBsAg) began as part of the mandatory screening of blood donors in the early 1980s. This endeavor significantly enhanced blood safety in terms of protecting people against the transmission of an HBV infection. However, several studies have revealed that a percentage of HBsAg donors who tested negative may in fact still be positive for the illness due to a presence of different antigens known as hepatitis B core antibodies (anti-HBc) meaning that it constitutes a possibility of circulating hepatitis B viral DNA (HBV-DNA), thus being a potential source of post transfusion hepatitis B (PTHB). Objectives: To determine the presence of anti-HBc and HBV-DNA in healthy HBsAg negative blood donors in the middle northern region of Libya (composed of the metropolitan cities of Misrata, Original Research ArticleKhoums, Zlitin, Sirite and surrounding small villages). Methods: The Misrata central blood bank (which services the middle northern region of Libya) provided A total of 979 HBsAg negative blood samples from healthy blood donors that were tested for anti-HBc using the VITROS® 3600 Immunodiagnostic System. The reactive samples were then further tested for the presence of HBV-DNA. Results: From the sample of 979, 38 of whom (3.9%) were anti-HBc positive. One sample tested positive for HBV-DNA by PCR (polymers chain reaction) from the anti-HBc positive samples indicating (2.6%) of the subgroup of anti-HBc positive samples and 0.1% from the whole sample population screened. Conclusion: Despite blood donors being HBsAg-negative in the middle northern region of Libya, 3.9% had anti-HBc, of which 2.6% of the anti-HBc positive donors had detectable HBV DNA. Further studies are needed to determine the actual yield of including an anti-HBc test in routine screening of blood donors.

No abstract

No abstract